Industry News
Biotechnology Industry News
After one HBV flop, Assembly Biosciences forced to drop a hepatitis asset amid safety woes
After one HBV flop, Assembly Biosciences forced to drop a hepatitis asset amid safety woes badams Thu, 09/02/2021 - 05:59
Exit of Avidity CMO on cusp of first clinical trial sparks stock rout
Exit of Avidity CMO on cusp of first clinical trial sparks stock rout ntaylor Thu, 09/02/2021 - 05:44
HebeCell lands $53M, Chinese collaborator to make a splash in busy CAR-NK space
HebeCell lands $53M, Chinese collaborator to make a splash in busy CAR-NK space ntaylor Wed, 09/01/2021 - 08:25
After cutting dose because of deaths, Astellas pauses gene therapy trial as new liver issue arises
After cutting dose because of deaths, Astellas pauses gene therapy trial as new liver issue arises ntaylor Wed, 09/01/2021 - 06:33
J&J’s HIV vaccine fails phase 2b, extending long wait for an effective jab
J&J's HIV vaccine fails phase 2b, extending long wait for an effective jab ntaylor Tue, 08/31/2021 - 08:17
GSK, Korean biotech SK go head-to-head against AstraZeneca’s COVID-19 shot with their experimental vaccine
GSK, Korean biotech SK go head-to-head against AstraZeneca's COVID-19 shot with their experimental vaccine badams Tue, 08/31/2021 - 08:08
A year after a death and accompanying trial hold, Poseida hopes for reprieve with early solid tumor CAR-T data
A year after a death and accompanying trial hold, Poseida hopes for reprieve with early solid tumor CAR-T data badams Tue, 08/31/2021 - 05:39
The descent of van de Stolpe: Galapagos CEO exits after R&D setbacks wipe out billions in value
The descent of van de Stolpe: Galapagos CEO exits after R&D setbacks wipe out billions in value ntaylor Tue, 08/31/2021 - 04:37
Brain cancer biotech Ziopharm snaps up new CEO from Kuur Therapeutics
Brain cancer biotech Ziopharm snaps up new CEO from Kuur Therapeutics klahucik Mon, 08/30/2021 - 09:48
Ziopharm snaps up new CEO from Kuur Therapeutics
Ziopharm snaps up new CEO from Kuur Therapeutics klahucik Mon, 08/30/2021 - 09:48
Pfizer’s abrocitinib beats blockbuster Dupixent in phase 3 eczema trial, but key questions remain
Pfizer's abrocitinib beats blockbuster Dupixent in phase 3 eczema trial, but key questions remain ntaylor Mon, 08/30/2021 - 08:44
SPAC backs Revelation to tackle respiratory viral infections
SPAC backs Revelation to tackle respiratory viral infections ntaylor Mon, 08/30/2021 - 08:02
Thwarting a cancer-promoting enzyme with a 2-pronged strategy to induce cell death
Thwarting a cancer-promoting enzyme with a 2-pronged strategy to induce cell death arlene.weintraub Fri, 08/27/2021 - 10:59
BeyondSpring, flying high from phase 3 success, sells Chinese rights to cancer drug
BeyondSpring, flying high from phase 3 success, sells Chinese rights to cancer drug ntaylor Fri, 08/27/2021 - 08:11
Agenus, with FDA approval in sight, showcases anti-PD-1 data
Agenus, with FDA approval in sight, showcases anti-PD-1 data ntaylor Fri, 08/27/2021 - 05:40
AstraZeneca’s $39B Alexion buyout bears fruit, yielding late-phase win for potential blockbuster rare disease drug
AstraZeneca's $39B Alexion buyout bears fruit, yielding late-phase win for potential blockbuster rare disease drug ntaylor Thu, 08/26/2021 - 07:37
Sesen, still reeling from FDA rejection, pulls filing for EU approval of cancer drug
Sesen, still reeling from FDA rejection, pulls filing for EU approval of cancer drug ntaylor Thu, 08/26/2021 - 06:06
Replimune axes CMO role and CMO Pirzkall along with it
Replimune axes CMO role and CMO Pirzkall along with it badams Thu, 08/26/2021 - 04:12
Unraveling the link between migraines and protection against diabetes
Unraveling the link between migraines and protection against diabetes klahucik Wed, 08/25/2021 - 11:46
Bristol-backed Cardior gets $75M to run midphase antisense heart failure trial
Bristol-backed Cardior gets $75M to run midphase antisense heart failure trial ntaylor Wed, 08/25/2021 - 08:05